Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has ...

The vaccines subsector received a big fillip from Covid, but its potential extends far beyond combating pandemics. Dr Mike ...

Genmab is discontinuing development of acasunlimab after a pipeline review, pivoting focus to other oncology antibodies.

Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...

Scientists at MIT and Stanford have unveiled a promising new way to help the immune system recognize and attack cancer cells more effectively. Their strategy targets a hidden “off switch” that tumors ...

The American Lung Association encourages people who use tobacco and nicotine products to make a resolution to quit in 2026, provides free resources CHICAGO, Dec. 16, 2025 /PRNewswire/ -- Currently, 16 ...

Large doses of vitamin C may provide our lungs with a degree of protection from the harmful effects of fine particles in the air. Referred to as PM2.5, in reference to their micrometer-wide particle ...

AI tools designed to diagnose cancer from tissue samples are quietly learning more than just disease patterns. New research shows these systems can infer patient demographics from pathology slides, ...

Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how ...

A study led by researchers at Moffitt Cancer Center found that normal cells surrounding a tumor, known as cancer-associated ...

From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...